Liver cancer is heavy! Cinda biology Dabershu® joint da ® first-line treatment of advanced hepatocellular carcinoma Phase III research was successful!

September 29, 2020 // -- Innovent Biologics recently announced the evaluation of PD-1 inhibitor Tyvyt®® A® randomized, open-label Phase III clinical study (ORIENT-32) in the first-line treatment of advanced hepatocellular carcinoma (HCC) reached a predefined non-progression lifetime (PFS) and total survival (OS) primary study endpoint during in-period analysis.
particularly noteworthy is that this is the first Phase III study in the world where the first phase HCC of PD-1 inhibitor combination therapy reaches the primary study endpoint.
is jointly ® by Xinda Bio and Lilly.
an in-period analysis conducted by the Independent Data Monitoring Board (IDMC), the combined treatment of Dabershu® and D'Athani® has significantly extended the non-Progress Lifetime (PFS) and Total Lifetime (OS) meet preset efficiency standards, and safety characteristics are consistent with previously reported Dabershu ® and Dawon ® studies, with no new safety signals.
the findings will be presented at an academic conference in the near future.
In line with IDMC's recommendations, Thyda Bio plans to communicate with the National Drug Administration (NMPA) Drug Review Center (CDE) about submitting a new adaptation application from Dabershu ®Yulti-Davyon® for first-line treatment of advanced HCC.
cancer is a common digestive system malignancies in the world, China's liver cancer patients accounted for about half of the global number of liver cancer, liver cancer seriously threatens the lives and health of our people.
pathological types of liver cancer are mainly hepatocellular carcinoma (HCC), accounting for 85%-90%, and a few are liver bile tube cancer (ICC) and HCC-ICC hybrids.
in China, HCC is mainly caused by hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection.
(® single anti-injection) is an innovative biologic drug of international quality developed jointly by Xinda Bio and Lilly Pharmaceuticals in China.
the first adaptation to be approved for the drug was relapsed/resuscipable classic Hodgkin's lymphoma, which was selected in the 2019 edition of the China Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of lymphoma.
2019 health-care talks, Dabershu was ® the only PD-1 inhibitor to enter the nation's health-care program.
In April 2020, NMPA officially accepted applications for new adaptations for the first-line treatment of non-squamous non-small cell lung cancer by Dabershu® (Syndicated Monoantigen Injection) Joint Libitai ® (Injected with Pythyrox di sodium) and platinum chemotherapy.
In May 2020, the Phase III study on the first-line treatment of squamous non-small cell lung cancer in Dabershu ®® (Syndili monoantigen injection) and the phase III study on the first-line treatment of squamous non-small cell lung cancer in injectable chemotherapy reached the end of the main study, as did the OR-2 study on the second-line treatment of advanced/metastatic esophageal squamous cancer in Dabershu ® (Syndili monoigenic injection).
In August 2020, NMPA officially accepted applications for new adaptations to Dabershu® (Syndicated Monoantigen Injection) Joint Choice ® (Injection with Gistabin) and platinum chemotherapy for first-line treatment of squamous non-small cell lung cancer.
Dabershu® (Syndili monoantigen injection) is a human immunoglobulin G4 (IgG4) monoclonal antibody that specificly binds to PD-1 molecules on the surface of T cells, thereby blocking the PD-1/programmed death complex 1 (Programmed Death-Ligand 1), which causes tumor immunity. PD-L1) path, reactivates the anti-tumor activity of lymphocytes, thus achieving the goal of treating tumors.
more than 20 clinical studies, more than 10 of which are registered clinical trials, are currently under way to assess the anti-tumor effects of Syndication on a wide range of solid and blood tumors.
Xinda Bio is also conducting clinical research on Xindili monoantigen injections around the world.
is ® biosynthic drug for beval-beaded monoinjeants, also known as recombinant anti-VEGF humanized monoclonal antibody injections.
VEGF is an important factor in angiogenesic process and is highly expressed in most human tumor endoblasts. since its launch, the
original drug beva bead monoantigen injection (Chinese commodity name: avetin ®) has been approved worldwide for the treatment of non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, peritiotic cancer and other solid tumors, its remarkable efficacy and good safety has been widely recognized.
() Origin: Thyme Creatures.